Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Lillian M SmythKenji TamuraMafalda OliveiraEva Ciruelos GilIngrid A MayerMarie-Paule SablinLaura BiganzoliHelen J AmbroseJack AshtonAlan BarnicleDes D CashellClaire CorcoranElza C de BruinAndrew FoxleyJoana HauserJustin P O LindemannRhiannon MaudsleyRobert McEwenMichele MoschettaMartin PassVicky RowlandsGaia SchiavonUdai BanerjiMaurizio ScaltritiBarry S TaylorSarat ChandarlapatyJosé BaselgaDavid M HymanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Capivasertib demonstrated clinically meaningful activity in heavily pretreated patients with AKT1 E17K-mutant ER+ MBC, including those with prior disease progression on fulvestrant. Tolerability and activity appeared improved by the combination.